The OSUCCC Analytical Cytometry Shared Resource (ACSR) is an extensive, institutionally-supported shared service. This core provides one of the only means of rapidly and accurately analyzing multiple characteristics of biological particles while also being able to rapidly, accurately, and with high purity (>98%) sort out pure populations of cells of interest based on parameters designated by the investigator. Furthermore, this service provides OSUCCC members with the ability to obtain viable, sterile and pure populations of cells so that they may be individually cloned, can be assessed for immunological function, or can be examined for specific biochemical properties with minimal manipulations, compared to magnetic bead technologies. This shared resource has five primary goals: 1) Provide state of the art flow cytometry analysis and sorting on a fee-for-service basis;2) Provide individual training followed by 24-hour access to flow cytometry instrumentation for researchers who wish to conduct their own analysis;3) Develop and provide educational and training opportunities for new and experienced resource users as well as forums to introduce new instrumentation, technologies and reagents to OSUCCC investigators;4) Obtain and provide state-of-the-art equipment to support high quality cancer research for OSUCCC members;and 5) Introduce new, or pre-commercial, emerging technology to support high quality cancer research for OSUCCC members. The ACSR main facility is centrally located and has eight flow cytometry instruments, four of which are capable of sorting. Two flow cytometer analyzers are available for independent (24 hour access) and assisted analysis. In addition, commercial and prototype magnetic separation and analysis equipment is available. Five'of these instruments were purchased with institufional support of approximately $1,358,000 in the last four years. In order to meet the needs of heavy users and maintain adequate space and access, the ACSR has two satellite facilifies located in the James Cancer Hospital (JCH) and the OSU College of Veterinary Medicine (CVM). The CVM has three flow cytometers, one of which is equipped to safely sort virus infected cells. The ACSR Director is Jeffrey Chalmers, Ph.D. with a manager, Bryan McElwain, and two additional staff. The CVM satellite is managed by A. Nicole White and has an additional technician. In addition, this past year Mary Jo Burkhard, D.V.M., Ph.D. was recruited as a co-investigator in the ACSR focused on education and outreach. The ACSR continues to provide critical support to the investigators and scientific programs, including 14 clinical studies acfively using the services of the ACSR This past year, nearly 75% of the ACSR usage was from 63 CCSG peer-reviewed, funded OSUCCC investigators from all six programs who consumed over 4,300 hours of service, yet only 23.4% of the support came from the CCSG.

Public Health Relevance

The ACSR provides instrumentation and technical operation/support for cell identification, characterization and cell separation to OSUCCC members and the University community. The ACSR, through exceptional institutional support and experienced leadership, is designed to provide affordable and high quality service in each of these areas, based on a cost-effective charge-back system. This ACSR provides critical support to OSUCCC scientific programs and clinical studies, while contributing outstanding technical expertise to high quality scientific cancer research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016058-38
Application #
8601804
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
38
Fiscal Year
2014
Total Cost
$94,642
Indirect Cost
$32,582
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
White, Brian S; Lanc, Irena; O'Neal, Julie et al. (2018) A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5. Blood Cancer J 8:35
Owen, Dwight; Chaft, Jamie E (2018) Immunotherapy in surgically resectable non-small cell lung cancer. J Thorac Dis 10:S404-S411
O'Brien, Susan M; Jaglowski, Samantha; Byrd, John C et al. (2018) Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials. JAMA Oncol 4:712-716
Guo, Sijin; Piao, Xijun; Li, Hui et al. (2018) Methods for construction and characterization of simple or special multifunctional RNA nanoparticles based on the 3WJ of phi29 DNA packaging motor. Methods 143:121-133
Sadowski, Abbey R; Gardner, Heather L; Borgatti, Antonella et al. (2018) Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma. BMC Vet Res 14:250
Barredo, Julio C; Hastings, Caroline; Lu, Xiamin et al. (2018) Isolated late testicular relapse of B-cell acute lymphoblastic leukemia treated with intensive systemic chemotherapy and response-based testicular radiation: A Children's Oncology Group study. Pediatr Blood Cancer 65:e26928
Kim, So-Youn; Nair, Devi M; Romero, Megan et al. (2018) Transient inhibition of p53 homologs protects ovarian function from two distinct apoptotic pathways triggered by anticancer therapies. Cell Death Differ :
Yadav, Marshleen; Song, Feifei; Huang, Jason et al. (2018) Ocimum flavone Orientin as a countermeasure for thrombocytopenia. Sci Rep 8:5075
Siegel, Marni B; He, Xiaping; Hoadley, Katherine A et al. (2018) Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer. J Clin Invest 128:1371-1383
Cui, Tiantian; Srivastava, Amit Kumar; Han, Chunhua et al. (2018) DDB2 represses ovarian cancer cell dedifferentiation by suppressing ALDH1A1. Cell Death Dis 9:561

Showing the most recent 10 out of 2602 publications